Skip to main content

Table 2 Overall dosimetric parameters (Mean ± StandardDeviation)

From: Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy

Structure

Parameter

All cases

Larynx

Oropharynx

Nasopharynx

Hypopharynx

Oral cavity

PTV_69.96Gy

Volume [cm3]

263 ± 147

233 ± 168

273 ± 141

273 ± 131

 

Mean [Gy]

69.96

69.96

69.96

69.96

 

D2% [Gy]

72.5 ± 0.8

72.4 ± 0.7

72.5 ± 0.8

72.8 ± 0.9

 

D98% [Gy]

65.3 ± 1.3

65.7 ± 1.0

65.3 ± 1.4

65.2 ± 1.0

 

Std.Dev. [Gy]

1.7 ± 0.4

1.6 ± 0.3

1.7 ± 0.4

1.9 ± 0.5

PTV_54.45Gya

Volume [cm3]

442 ± 198

459 ± 195

413 ± 181

477 ± 222

 

Mean [Gy]

56.2 ± 2.0

56.2 ± 1.6

56.3 ± 2.1

56.2 ± 2.1

 

D98% [Gy]

50.9 ± 1.2

50.9 ± 1.1

51.0 ± 1.0

50.9 ± 1.6

 

Std.Dev. [Gy]

2.8 ± 1.0

2.9 ± 0.9

2.8 ± 0.9

2.8 ± 1.0

Spinal Cord

D2% [Gy]

36.2 ± 8.1

36.5 ± 5.4

34.6 ± 6.4

38.9 ± 11.5

Brain Stem

D2% [Gy]

34.3 ± 15.9

27.4 ± 12.9

29.1 ± 14.6

47.7 ± 11.3

Constrictor inf.

Mean [Gy]

48.6 ± 13.8

66.6 ± 4.9

44.3 ± 9.4

39.5 ± 10.6

Constrictor mid.

Mean [Gy]

59.2 ± 11.0

67.5 ± 5.1

58.8 ± 9.5

52.4 ± 12.3

Constrictor sup.

Mean [Gy]

62.9 ± 8.8

57.0 ± 9.1

66.1 ± 4.5

62.4 ± 11.1

Oral Cavity

Mean [Gy]

44.9 ± 8.2

37.4 ± 6.5

49.9 ± 6.2

43.0 ± 6.4

 

V50Gy [%]

40.5 ± 18.7

23.7 ± 12.5

52.6 ± 15.5

34.6 ± 12.8

Parotids

Mean [Gy]

26.0 ± 7.2

22.5 ± 3.8

27.4 ± 8.0

26.6 ± 7.0

Submandibulars

Mean [Gy]

61.1 ± 10.0

59.2 ± 8.0

63.2 ± 8.1

59.3 ± 13.3

Larynx

Mean [Gy]

38.7 ± 9.0

51.6 ± 13.6b

36.9 ± 7.5

38.1 ± 5.8

Eyes

Mean [Gy]

 

1.3 ± 0.2

1.2 ± 0.4

6.1 ± 6.8

Thyroid

Mean [Gy]

43.9 ± 8.2

47.4 ± 9.4

43.0 ± 7.8

42.5 ± 6.7

  1. asubtracting the PTV_69.96Gy volume
  2. bonly hypopharyngeal tumours